NCT01773187 2020-09-29Pacritinib Versus Best Available Therapy to Treat MyelofibrosisCTI BioPharmaPhase 3 Terminated327 enrolled 11 charts
NCT02292446 2019-07-18Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.NovartisPhase 3 Completed161 enrolled 14 charts
NCT01259856 2019-04-30Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)Icahn School of Medicine at Mount SinaiPhase 3 Completed168 enrolled 16 charts
NCT01243944 2019-03-06Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)Incyte CorporationPhase 3 Completed222 enrolled 21 charts
NCT01632904 2017-11-14Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyIncyte CorporationPhase 3 Completed110 enrolled 11 charts
NCT00719563 2017-02-09American Ginseng in Treating Patients With Fatigue Caused by CancerAlliance for Clinical Trials in OncologyPhase 3 Completed364 enrolled 29 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts
NCT00666211 2012-09-06Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainVanderbilt-Ingram Cancer CenterPhase 3 Completed98 enrolled 14 charts